IQVIA (NYSE:IQV) Given New $225.00 Price Target at JPMorgan Chase & Co.

IQVIA (NYSE:IQV) had its target price decreased by JPMorgan Chase & Co. from $255.00 to $225.00 in a report released on Friday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the medical research company’s stock.

Other equities research analysts have also recently issued research reports about the stock. TD Cowen increased their target price on shares of IQVIA from $215.00 to $245.00 and gave the company a “hold” rating in a research note on Thursday, January 22nd. HSBC raised IQVIA from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $195.00 to $235.00 in a report on Thursday, October 9th. Mizuho set a $266.00 price target on shares of IQVIA in a research note on Friday, January 9th. Robert W. Baird set a $258.00 target price on IQVIA and gave the stock an “outperform” rating in a report on Wednesday, October 29th. Finally, Citigroup lowered their target price on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a report on Friday. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $241.75.

IQVIA Price Performance

Shares of IQV opened at $187.50 on Friday. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.70 and a current ratio of 0.75. The firm has a market cap of $31.93 billion, a PE ratio of 23.85, a PEG ratio of 1.84 and a beta of 1.37. IQVIA has a twelve month low of $134.65 and a twelve month high of $247.04. The firm’s 50 day moving average price is $228.03 and its 200 day moving average price is $209.61.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.40 by $0.02. The firm had revenue of $4.36 billion for the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The business’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the firm posted $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, research analysts expect that IQVIA will post 10.84 EPS for the current fiscal year.

Institutional Investors Weigh In On IQVIA

Several large investors have recently bought and sold shares of IQV. Brighton Jones LLC grew its position in IQVIA by 244.4% in the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after purchasing an additional 2,537 shares in the last quarter. Empowered Funds LLC grew its holdings in shares of IQVIA by 102.1% in the 1st quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock valued at $1,715,000 after acquiring an additional 4,915 shares in the last quarter. Sivia Capital Partners LLC acquired a new stake in shares of IQVIA in the second quarter valued at about $514,000. DAVENPORT & Co LLC raised its holdings in IQVIA by 6.7% during the second quarter. DAVENPORT & Co LLC now owns 2,449 shares of the medical research company’s stock worth $386,000 after acquiring an additional 153 shares in the last quarter. Finally, KLP Kapitalforvaltning AS boosted its position in IQVIA by 1.7% during the second quarter. KLP Kapitalforvaltning AS now owns 64,675 shares of the medical research company’s stock valued at $10,192,000 after purchasing an additional 1,100 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA News Roundup

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: Q4 results beat consensus: IQV reported Q4 EPS of $3.42 and revenue of $4.36B, both above estimates and showing double‑digit Y/Y sales growth — a core reason buyers are stepping in. IQVIA Holdings (IQV) Q4 Earnings and Revenues Top Estimates
• Positive Sentiment: FY‑2026 guidance modestly raised on revenue and EPS ranges (EPS 12.55–12.85; revenue $17.2B–$17.4B) — guidance came in around or slightly above Street revenue/consensus EPS, supporting near‑term sentiment. IQVIA’s (NYSE:IQV) Q4 CY2025 Sales Top Estimates
• Positive Sentiment: Jefferies lowered its price target to $255 but kept a “buy” rating — that still implies sizable upside vs. the current price and helps underpin demand from buy‑side holders. Jefferies PT Cut (Benzinga)
• Neutral Sentiment: Citigroup trimmed its price target to $200 and moved to “neutral” — a calibration of expectations but not a full sell signal. Citigroup PT Change (Benzinga)
• Neutral Sentiment: Analyst commentary and value‑style writeups (Zacks) highlight IQV as a longer‑term value play based on style scores — useful for longer‑horizon investors rather than short‑term movers. Why IQVIA Is a Top Value Stock (Zacks)
• Negative Sentiment: IQV warned that higher interest expenses will weigh on annual profit, and Reuters notes the company forecast annual profit below Street expectations — this is increasing focus on leverage and interest‑rate sensitivity. IQV Forecasts Weak Annual Profit (Reuters)
• Negative Sentiment: Market headlines flagged that shares fell after management’s outlook for adjusted earnings missed some expectations — that knee‑jerk reaction pressured the stock before buyers re‑entered. Shares Down After Outlook Misses (MarketWatch)
• Negative Sentiment: BTIG cut its rating to neutral citing sector headwinds — another signal that some sell‑side shops are taking a more cautious near‑term stance. BTIG Cuts Rating to Neutral (MSN)

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.